PXS 5382A

Drug Profile

PXS 5382A

Alternative Names: PXS-5382; PXS-5382A

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaxis
  • Class Antifibrotics; Pyrans; Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors; Protein-lysine 6-oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis; Renal fibrosis
  • Preclinical Cancer

Most Recent Events

  • 14 Dec 2017 Pharmaxis and Synairgen amend their agreement to co-develop LOXL2 inhibitors for Pulmonary fibrosis
  • 30 Oct 2017 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in Australia (PO) (ACTRN12617001564347)
  • 12 Oct 2017 Preclinical trials in Non-alcoholic steatohepatitis in Australia (PO), before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top